Rapid Therapeutic Science Laboratories, Inc.
RTSL
$0.0074
$0.000.00%
OTC PK
| 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -20.18% | -88.22% | -95.11% | -29.55% | -76.79% |
| Depreciation & Amortization | 0.00% | 0.00% | -1,150.91% | 396.36% | 9.09% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -83.49% | -87.55% | -104.35% | -24.85% | -75.91% |
| Operating Income | 83.49% | 87.55% | 104.35% | 24.83% | 75.89% |
| Income Before Tax | 226.09% | 112.11% | 104.03% | 61.07% | 93.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 226.09% | 112.11% | 104.03% | 61.07% | 93.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 226.09% | 112.11% | 104.03% | 61.07% | 93.13% |
| EBIT | 83.49% | 87.55% | 104.35% | 24.83% | 75.89% |
| EBITDA | 87.58% | 88.22% | 105.36% | 25.21% | 76.78% |
| EPS Basic | 216.67% | 111.76% | 104.02% | 61.14% | 93.07% |
| Normalized Basic EPS | 216.67% | 111.76% | 103.98% | 61.15% | 93.07% |
| EPS Diluted | 216.67% | 111.76% | 104.02% | 61.14% | 93.07% |
| Normalized Diluted EPS | 216.67% | 111.76% | 103.98% | 61.15% | 93.07% |
| Average Basic Shares Outstanding | 7.38% | 3.04% | 0.02% | 0.05% | 0.12% |
| Average Diluted Shares Outstanding | 7.38% | 3.04% | 0.02% | 0.05% | 0.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |